Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07624227 · ClinicalTrials.gov registry record · Phase 1

The Impact of Cobenfy Maintenance on Cocaine's Effects

A Phase 1 study, sponsored by Joshua A. Lile, Ph.D..

Not yet
Registry status
Phase 1
Development phase
32
Enrollment target

NCT07624227 is a Phase 1 study that has not yet begun recruiting, run by Joshua A. Lile, Ph.D.. The registered enrollment target is 32 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07624227, a Phase 1 study, has not yet begun recruiting, sponsored by Joshua A. Lile, Ph.D..

NOT YET RECRUITING
Registry status
Phase 1
Development phase
32 participants
Enrollment target

Study Summary

The goal of this clinical trial is to learn if Cobenfy influences the effects of cocaine in people with cocaine use disorder. This trial will also provide information about the safety and tolerability of combining Cobenfy and cocaine. Researchers will compare Cobenfy to a placebo (a look-alike substance that contains no drug) to see if Cobenfy is a safe, tolerable and effective at blocking cocaine's effects in participants with cocaine use disorder. Participants will: * Participate in an 11-day inpatient trial * Take Cobenfy or placebo twice per day. * Participate in experimental sessions to test the effects of Cobenfy (or placebo) on the response to cocaine and cocaine self-administration.

Interventions

  • DRUG Placebo
  • DRUG Cobenfy

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2026-08-01
Est. Completion 2032-06-30
Phase Phase 1

Sponsor

Joshua A. Lile, Ph.D.

7 total trials

What the Registry Record Tells You About NCT07624227

The ClinicalTrials.gov registry entry for NCT07624227 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joshua A. Lile, Ph.D., which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT07624227 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07624227 about?

NCT07624227 is a clinical study titled "The Impact of Cobenfy Maintenance on Cocaine's Effects". The goal of this clinical trial is to learn if Cobenfy influences the effects of cocaine in people with cocaine use disorder. This trial will also provide information about the safety and tolerability of combining Cobenfy and cocaine. Researchers will compare Cobenfy to a placebo (a look-alike subs...

What is the current status of trial NCT07624227?

This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-08-01. Estimated completion is 2032-06-30.

What interventions are being tested in trial NCT07624227?

The interventions under investigation include: Placebo (DRUG), Cobenfy (DRUG).

Who is sponsoring clinical trial NCT07624227?

This trial is sponsored by Joshua A. Lile, Ph.D., which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.